Opdivo
(nivolumab)10 ML nivolumab 10 MG/ML Injection [Opdivo]12 ML nivolumab 10 MG/ML Injection [Opdivo]
View 2 more
NO BOXED WARNING
Dosage & administration
biomarker testing
Opdivo clinical details
Genetic testing requirements were obtained from the NCCN guidelines for each cancer type.
drug label
Opdivo prescribing information
prior authorization
Opdivo prior authorization resources
Most recent Opdivo prior authorization forms
View By PayerVerified: Nov 27, 2023Cigna - Opdivo Prior Authorization Form
Verified: Nov 20, 2023Aetna - Opdivo Prior Authorization Form
Verified: Nov 19, 2023Aetna - Medicare Part B Opdivo Prior Authorization Form
Learn More
If available, these templates are provided by the brand to help you navigate insurance, especially with newer drugs.
Benefits investigation
Learn More
Benefits investigations are conducted to determine whether a therapy is covered under a patient's insurance, if a prior authorization is required, and which specialty pharmacies are preferred.
Reimbursement help (FRM)
Learn More
Some brands offer a field reimbursement manager who will work with your clinical staff and preferred pharmacy to help make sure patients don't fall through the cracks.
financial assistance
Opdivo financial assistance options
Co-pay savings program
commercial only
Learn More
Overview
- Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)
Patient benefit
- A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max
Patient eligibility
- Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
- Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
- May never be used with government insurance
How to sign up
- Cards may be downloadable digital cards or hard copies
- Some pharmacos offer debit cards with pre-loaded copay benefit
- Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
- Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form
Foundation programs
under insured
no insurance
goverment insurance
65+
Learn More
Overview
- Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
- These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned
Patient benefit
- Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted
Patient eligibility
- Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.
How to sign up
- Patients submit proof of out-of-pocket drug costs to charities for reimbursement
patient education
Opdivo patient education
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link
Patient toolkit
Receiving Treatment: Opdivo + Chemotherapy Before Surgery (Neoadjuvant Treatment of Early-Stage NSCLC)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Receiving Treatment: Opdivo + Yervoy (1L mNSCLC, PD-L1 Positive)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Receiving Treatment: Opdivo + Yervoy (1L r/m NSCLC Regardless of PD-L1 Expression)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Receiving Treatment: Opdivo Monotherapy (2L mNSCLC)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Receiving Treatment: Opdivo + Yervoy (1L Intermediate or Poor Risk Advanced RCC)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Receiving Treatment: Opdivo + Cabometyx (1L Advanced RCC)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Receiving Treatment: Opdivo Monotherapy (Advanced RCC)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Receiving Treatment: Opdivo Monotherapy (Adjuvant Treatment of Completely Resected ESO or GEJ Cancer)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Receiving Treatment: Opdivo + Chemotherapy (1L Metastatic Gastric, GEJ, or Esophageal Adenocarcinomas)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Receiving Treatment: Opdivo + Chemotherapy (1L Metastatic Esophageal Squamous Cell Carcinoma [ESCC])
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Receiving Treatment: Opdivo + Yervoy (1L mESCC)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Receiving Treatment: Opdivo + Chemotherapy (1L mESCC, PD-L1 Positive)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
Receiving Treatment: Opdivo + Yervoy (Advanced Melanoma)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link